Next Blood Draw — Early April 2026

Timing: Early April (post-Lent, ~7 weeks into OMAD) Prep: 12h+ fast, morning draw (~8am) Previous draw: March 10, 2026 (Quest)


Tier 1 — Core Metabolic Tracking (repeat from March)

These are your monthly tracking markers per the Lent protocol.

Marker Why March Result Target
Fasting insulin Primary metabolic metric 25.4 <15 by Pascha
Triglycerides Metabolic syndrome indicator 143 <100
Fasting glucose IR proxy 110 <95
HbA1c 3-month glucose average 5.8% <5.7%
Cystatin C + eGFR Kidney function (quarterly) 1.02 / eGFR 84 Stable

Tier 2 — Genome-Informed (NEW)

These are new tests motivated by your 23andMe analysis from March 18.

Marker Why Genetic Basis Est. Cost
Serum AAT (alpha-1 antitrypsin) Pi*Z heterozygous carrier (rs28929474 CT). Could explain chronic ALT elevation via hepatocyte ER stress. SERPINA1 het ~$20-30
Methylmalonic acid (MMA) Functional B12 tissue marker. Serum B12 is unreliable given your TCN2 het + MTRR het stack. TCN2, MTRR, FUT2, CBS hets ~$30
Homocysteine Functional B12/folate marker. Also cardiovascular risk. Elevated = methylation bottleneck. Same B12 pathway stack ~$20-30
Serum B12 Baseline, but less informative than MMA. Get it anyway for completeness. TCN2 het ~$15
Folate (serum or RBC) Pairs with homocysteine. MTHFR A1298C het = mild folate metabolism effect. MTHFR A1298C het ~$15

Tier 3 — Liver Deep Dive (follow-up)

Marker Why March Result
ALT Track trend 39 (best ever)
AST AST/ALT ratio for staging 28
GGT Recommended March 7 but never ordered. Best NAFLD progression marker. Sensitive to alcohol, meds, bile duct issues. Never tested
Ferritin Tracking rebound post-donation 152

Tier 4 — Nice-to-Have

Marker Why
TSH Subclinical hypothyroid can mimic metabolic syndrome. Never been checked.
Free T3, Free T4 Full thyroid panel if TSH is abnormal
Vitamin D (25-OH) Genetic tendency toward lower levels (VDR/GC variants)
Uric acid Track trend (was 7.9 Jul → 7.0 Mar)
C-Peptide Repeat to track beta cell function (was 2.93)

Ordering Notes

What We’re Looking For

  1. Insulin trajectory — need to see continued decline toward <15. If it’s still >20 after 7 weeks OMAD, we need to intensify (longer fasts, add metformin discussion).
  2. MMA + homocysteine — if either is elevated, start methylcobalamin + methylfolate immediately. This could be an independent driver of your IR.
  3. AAT level — if low (<100 mg/dL), it confirms the Z allele is functionally relevant and partly explains ALT history. Would warrant hepatology follow-up.
  4. GGT — filling a gap. If elevated, suggests ongoing hepatobiliary stress beyond what ALT shows.
  5. Trig/glucose — confirm March improvement wasn’t a fluke.

Updates from March 18 Genome Deep Dive

Removed:

Added to Tier 4 (Nice-to-Have):

Marker Why
HDL-C CETP B2B2 genotype predicts naturally higher HDL. If HDL is low despite this, it’s a strong environmental signal.

New Context for Interpretation: